Loading company…
Octomera supports decentralized point-of-care production of cell and gene therapies.
Founded in 2022 and based in the US, Octomera LLC produces cell and gene therapy products and supports decentralized point-of-care production. Its services and flexible capacity are provided through OMPULS, or Octomera Mobile Processing Units & Labs. In January 2024, Orgenesis Inc. agreed to acquire a 25% stake from MM OS Holdings; following the transaction, Orgenesis was to own 100% of Octomera.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in